Healthcare provider profile · identity verified

Peter W Emery, MD

Internal Medicine · PORTLAND, ME · NPI 1649239765

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	794	225
Losartan Potassium	Losartan Potassium	511	161
Levothyroxine Sodium	Levothyroxine Sodium	460	119
Amlodipine Besylate	Amlodipine Besylate	443	122
Lisinopril	Lisinopril	348	100
Simvastatin	Simvastatin	305	84
Omeprazole	Omeprazole	281	90
Eliquis	Apixaban	254	74
Hydrochlorothiazide	Hydrochlorothiazide	252	80
Metoprolol Succinate	Metoprolol Succinate	216	61
Rosuvastatin Calcium	Rosuvastatin Calcium	209	62
Irbesartan	Irbesartan	193	69
Tamsulosin Hcl	Tamsulosin Hcl	170	52
Metformin Hcl	Metformin Hcl	140	40
Escitalopram Oxalate	Escitalopram Oxalate	139	38
Gabapentin	Gabapentin	138	47
Atenolol	Atenolol	118	33
Sertraline Hcl	Sertraline Hcl	114	33
Allopurinol	Allopurinol	112	30
Metoprolol Tartrate	Metoprolol Tartrate	112	30
Trazodone Hcl	Trazodone Hcl	84	32
Albuterol Sulfate Hfa	Albuterol Sulfate	78	42
Furosemide	Furosemide	75	25
Pantoprazole Sodium	Pantoprazole Sodium	74	22
Pravastatin Sodium	Pravastatin Sodium	74	22
Jardiance	Empagliflozin	67	22
Synthroid	Levothyroxine Sodium	67	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	66	18
Zolpidem Tartrate	Zolpidem Tartrate	61	27
Chlorthalidone	Chlorthalidone	60	18
Alendronate Sodium	Alendronate Sodium	55	18
Famotidine	Famotidine	55	17
Prednisone	Prednisone	53	30
Doxycycline Hyclate	Doxycycline Hyclate	52	47
Duloxetine Hcl	Duloxetine Hcl	52	14
Lorazepam	Lorazepam	52	28
Amoxicillin	Amoxicillin	46	31
Citalopram Hbr	Citalopram Hydrobromide	46	15
Finasteride	Finasteride	46	14
Metformin Hcl Er	Metformin Hcl	46	14
Buspirone Hcl	Buspirone Hcl	43	16
Ozempic	Semaglutide	41	suppressed
Potassium Chloride	Potassium Chloride	41	13
Amitriptyline Hcl	Amitriptyline Hcl	40	14
Venlafaxine Hcl Er	Venlafaxine Hcl	40	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	38	11
Tramadol Hcl	Tramadol Hcl	38	12
Montelukast Sodium	Montelukast Sodium	37	12
Bupropion Xl	Bupropion Hcl	36	13
Fluoxetine Hcl	Fluoxetine Hcl	35	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	34	32
Ezetimibe	Ezetimibe	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	31	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	31	23
Spironolactone	Spironolactone	31	11
Lansoprazole	Lansoprazole	29	suppressed
Xarelto	Rivaroxaban	29	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	28	28
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	14
Glipizide Er	Glipizide	26	suppressed
Mounjaro	Tirzepatide	26	suppressed
Valsartan	Valsartan	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	23	suppressed
Alprazolam	Alprazolam	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Meloxicam	Meloxicam	22	12
Warfarin Sodium	Warfarin Sodium	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	11
Carvedilol	Carvedilol	21	suppressed
Celecoxib	Celecoxib	21	suppressed
Tresiba Flextouch U-100	Insulin Degludec	21	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	16
Donepezil Hcl	Donepezil Hcl	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	14
Farxiga	Dapagliflozin Propanediol	17	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	16	13
Sildenafil Citrate	Sildenafil Citrate	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Verapamil Sr	Verapamil Hcl	15	suppressed
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Famciclovir	Famciclovir	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Oxycontin	Oxycodone Hcl	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Levoxyl	Levothyroxine Sodium	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Armour Thyroid	Thyroid,pork	12	suppressed
Estradiol	Estradiol	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Azithromycin	Azithromycin	11	11
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	11	suppressed
Nadolol	Nadolol	11	suppressed
Oxcarbazepine	Oxcarbazepine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error